Product Reports Resources Pricing Login Book a demo

Guardant Health

Biotech & Life Sciences · Palo Alto, United States · Founded 2012 · IPO 2018

Improving patient health through technology breakthroughs in oncology.

Valuation $22B
Revenue $1.34B

Talent graph

Guardant Health's talent

Book a demo to see the people
Employees mapped 4,699 incl. 18 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 12 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia 7 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

20 investors on Guardant Health's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage
Farzad (Zod) Nazem
frank malek
Osage University Partners
Sequoia

Global footprint

Where Guardant Health has talent and traffic

Workforce by country
🇺🇸 United States · Palo Alto HQ
Book a demo for the full country breakdown
Web traffic by country
51K monthly visits
across markets
🇺🇸 United States64.3%
🇬🇧 United Kingdom13.3%
🇯🇵 Japan4.5%
🇸🇬 Singapore3.9%
🇻🇳 Vietnam2.7%
Top 5 markets shown

Patent intelligence

$105M patent portfolio · 175 active families

Estimated portfolio value
$105M
0.47% of market cap · 4.5× larger than top peer Recursion Pharma ($23M)
175 active patent families
Where Guardant Health innovates BioinformaticsCellCell freeComputational biologyDisease

Where Guardant Health concentrates vs peers

Each axis is a top-10 topic across Guardant Health and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Guardant Health's 2 investments and acquisitions.

Every disclosed deal where Guardant Health appeared as a backer or acquirer, 2021–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

2 deals across Guardant Health's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where Guardant Health deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        Guardant Health's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        2 of 2 deals

        Market sentiment

        What the market is saying about Guardant Health

        An AI-synthesized read of the highest-engagement posts about Guardant Health on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Guardant Health on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.